Form 4: Altimmune Chief Medical Officer Reports Stock Transactions

Altimmune's Chief Medical Officer, Matthew Scott Harris, reported multiple transactions involving the company's stock, including the vesting of restricted stock units and purchases through the employee stock purchase plan.

Summary

• Matthew Scott Harris, Chief Medical Officer of Altimmune, Inc., filed a Form 4 detailing several transactions involving the company's common stock.
• These transactions include the vesting of restricted stock units (RSUs) on January 30, 2025, February 1, 2025 and February 2, 2025, resulting in the acquisition of 9,275, 6,166 and 7,775 shares respectively.
• Shares were also surrendered to cover taxes associated with the vesting of RSUs on the same dates.
• Additionally, Mr. Harris purchased 1,905 shares on January 31, 2025, through the company's Employee Stock Purchase Plan (ESPP) at a price of $5.18 per share.
• The ESPP purchase price was based on 85% of the closing price of the company's common stock on August 1, 2024.
• The reported transactions resulted in a net increase in Mr. Harris's direct holdings of Altimmune common stock.

Sentiment

Score: 7

Explanation: The document reflects routine stock transactions by an executive, which is generally neutral. The purchase of shares through the ESPP is a positive sign, while the sale of shares for tax purposes is a common practice.

Positives

• The vesting of restricted stock units indicates that the executive is meeting the conditions of their compensation package.
• The purchase of shares through the ESPP demonstrates the executive's confidence in the company's future.

Negatives

• The sale of shares to cover taxes associated with the vesting of RSUs reduces the overall increase in the executive's holdings.

Risks

• The sale of shares to cover taxes could be perceived negatively by some investors, although it is a common practice.
• The value of the shares is subject to market fluctuations, which could impact the executive's holdings.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and trading activity.

Comparison to Industry Standards

• The vesting of restricted stock units and participation in employee stock purchase plans are standard forms of compensation for executives in the biotechnology industry.
• The tax withholding process is also a standard practice when RSUs vest.
• The reported transactions are similar to those seen in other companies such as Moderna, BioNTech and Novavax, where executives regularly report stock transactions.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and trading activity.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Altimmune, Stock Transactions, Form 4, Restricted Stock Units, Employee Stock Purchase Plan, Insider Trading, Matthew Scott Harris, Chief Medical Officer